ATMP Interest Group
It is the Interest Group’s objective to
- provide a Europe-wide networking platform for persons involved in the development, manufacturing, quality management and marketing authorisation of Advanced Therapy Medicinal Products (ATMP) by facilitating effective and efficient communication between sciences, industry, competent authorities and the pharmacopoeias.
- promote active discussion on the latest regulatory requirements for ATMP within the European Union, US and world wide.
- identify and address regulatory, scientific and technical issues and challenges, including training needs.
History
The Regulation (EC) No 1394/2007 provides the overall legal framework on ATMPs to be placed on the community market. Concomitantly, the ECA began evaluating the interest in courses and additional activities on cell based products in 2008. However, the initial interest in such events was limited at the time. The main reason for this may have been that many companies were still in the early phase of development. Nevertheless, to keep their members informed about the ongoing developments, the ECA continued to include ATMP topics in their newsletters and organised courses on GMP for ATMP every two years.
Meanwhile, due to promising results and increasing investments in the development of ATMP, a growing number of institutions and companies have reached the phase of clinical testing and GMP compliant manufacturing, as well as marketing authorisation. This development has resulted in a rising interest of ECA members on the topic of ATMP.
With the European Commission draft Guideline on GMP for ATMP, which was discussed intensely during the ECA ATMP workshop in April 2017, GMP requirements came to be more under scrutiny. During this event, we requested feedback of the participants on whether an ECA Working Group on ATMP would be of interest. Several participants expressed their interest. At the same time, within the European Qualified Person Association, the QPs involved in ATMPs started an initiative to discuss the subject (especially within the IMP Working Group).
To coordinate the increasing interests, ECA decided to establish a joint ATMP Interest Group.
Interest Group Board
Chair:
Dr Sabine
Hauck
dequra pharma consult hauck, Germany
Vice Chair:
Dr Ulrike Herbrand
Charles River Laboratories, Germany
Dr Katja Aschermann
Astator, Germany
Dr Georg
Belke-Louis
Minaris, Germany
Prof Dr Martin Hildebrandt
TU Munich, Germany
Kati
Kebbel
Fraunhofer IZI, Germany
Dr Roland
Pach
Roche, Switzerland
Dr Christoph Peter
Peter Auditing GbR, Germany
Authority Representatives
Jan-Oliver
Karo
Paul-Ehrlich-Institute, German Federal Agency for Vaccines and Biomedicine
